Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdose docetaxel pharmacokinetics to individualize therapeutic docetaxel dosing
NL-OMON49402Phase 4Active, not recruiting
- Sponsor
- Meander Medical Center
- Start
- Sep 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel in breast cancer, prostate cancer (PCa) and non-small cell lung cancer (NSCLC), sponsored by Meander Medical Center. Primary endpoint: Pharmacokinetics of microdose and therapeutic dose docetaxel. Started Sep 2017; status: active, not recruiting.
02
Drugs
docetaxel
03
Conditions
breast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49402.